Brief: Prostatype Genomics Resolves Rights Issue Of SEK 27.3 Mln
April 15 (Reuters) - Prostatype Genomics AB PROGEN.ST: RESOLVES ON A RIGHTS ISSUE OF UNITS TO FUND COMPLETION OF US VALIDATION STUDY AND MEDICARE APPROVAL PROCESS AS WELL AS ONGOING COMMERCIALIZATION ACTIVITIES IN THE US AND EUROPE BOARD RESOLVES ON SEK 27.3 MILLION RIGHTS ISSUE Source text: ID:nMFNbJBrgZ Further company coverage: PROGEN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Prostatype Genomics AB
See all newsBrief: Prostatype Genomics Cannot Specify Timing For Final Medicare Decision
Brief: Prostatype Genomics Enters SEK 6.0 Mln Agreement With Vator Securities For To6
Brief: Prostatype Genomics AB H1 2026 Net Sales SEK 457,000
Brief: Prostatype Genomics Resolves On Directed Issue
Brief: Prostatype Genomics To Receive About SEK 47.4 Mln From Rights Issue